|
| |
Senior appointments further strengthen Pharmaceutical Profiles scientific
expertise
29 November 2007: Nottingham, UK: Dr Andrew Rankin joins
Pharmaceutical Profiles (Nottingham, UK) as Chief Scientific Officer. He brings
considerable R&D experience, spanning both academic and pharmaceutical
environments, having spent 14 years in leadership roles with Pfizer, from
pre-clinical and exploratory drug development through to successful global
regulatory approvals. Andrew will direct and develop the company’s scientific
innovation.
His extensive experience will enable him to build on existing strengths in human
drug absorption and oral formulation development at Pharmaceutical Profiles,
streamlining methods, saving time and improving the cost efficiency of the drug
development process.
In a second appointment, Dr Peter Scholes has taken up the position of Vice
President of Pharmaceutical Sciences. He assumes overall operational
responsibility for formulation, analytical and manufacturing functions within
Pharmaceutical Profiles. A pharmacist by background, Peter has considerable
hands-on, strategic and management experience.
Dr Mark Egerton, Chief Executive Officer of Pharmaceutical Profiles said: “We
are extremely pleased to welcome two experts of such high calibre to the company
and look forward to benefiting from their insight and experience as
Pharmaceutical Profiles continues its business growth.”
Pharmaceutical Profiles specializes in early clinical drug development. The
company uses patented technology and unique know-how to visualize and quantify
formulation performance in the clinic.
www.pharmprofiles.com
Text ends
For further information:
Press information
Richard Kent, Kapler Communications
Tel: +44 (0)1480 479 280 Fax: +44 (0) 1480 470 343
richard@kapleronline.com
Company contact:
Karen Jones PhD, Vice President, Marketing, Pharmaceutical Profiles Ltd
Tel: +44 (0)115 974 9000
karen.jones@pharmprofiles.com
| |
|
